MiNK Therapeutics, Inc. INKT

12.18 (0.12) (0.98%) as of 25 Sep
Market cap
$62.8M
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— 0.00 — — — — — —
P/S ratio
— 0.00 — — — — — —
P/FCF ratio
— 0.00 — — — — — —
P/Operating CF
— (83.09) — — — — — —
P/B ratio
— 0.00 — — — — — —
Price to Tangible BV
— 0.00 — — — — — —
EV/Sales
— 0.00 — — — — — —
EV/EBITDA
— 0.00 — — — — — —
EV/Operating CF
— (25.97) — — — — — —
EV/FCF
— (25.47) — — — — — —
Quick Ratio
— 0.04 0.19 2.36 1.55 0.30 0.66 1.03
Current Ratio
— 0.12 0.29 2.41 1.61 0.32 0.72 1.06
Net Debt/EBITDA
— (1.19) (2.82) 1.38 0.64 0.15 (0.03) 1.07
Debt/Assets
0.00% 2,046.79% 962.07% 0.00% 0.00% 0.00% 86.08% 0.00%
Debt/Equity
— (0.74) (0.81) 0.00 0.00 0.00 (0.25) 0.00
Asset Turnover
— 1.05 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
— 0.63 0.51 0.42 0.67 0.70 0.89 0.47
Capex/Depreciation
— (11.59) (1.73) (3.19) (2.05) (0.36) 0.00 0.00
Interest Coverage
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— 52.77% 36.00% 200.76% (239.49%) 243.36% 57.30% 73.90%
ROA
— (3,636.98%) (553.84%) (134.89%) (90.71%) (172.59%) (209.96%) (125.20%)
ROIC
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— 389.56% 167.98% (127.07%) (318.50%) 327.84% 870.51% (1,034.81%)
Average Days of Receivables
— 0.00 0.00 0.00 — — — —
Research and Development Expense of Revenue
— 2,850.07% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 555.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 31.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Graham Net Nets
— (0.27) — — — — — —
Graham Number
— 0.00 — — — — — —
Earnings Yield
— (8.47%) — — — — — —
Free Cash Flow Yield
— (4.51%) — — — — — —
Revenue per Share
— 0.29 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
— (6.21) (3.46) (4.93) (5.60) (4.59) (2.53) (1.39)
Capex per Share
— (0.18) (0.04) (0.10) (0.07) (0.02) 0.00 0.00
Free Cash Flow per Share
— (6.39) (3.50) (5.02) (5.68) (4.61) (2.53) (1.39)
Cash per Share
— 0.12 1.12 14.94 5.83 0.98 1.21 3.13
Shareholders Equity per Share
— (15.10) (22.35) 9.14 (0.12) (5.25) (5.19) (3.33)
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— (15.10) (22.35) 9.14 (0.12) (5.25) (5.19) (3.33)
Free Cash Flow
— (15.37) (8.43) (13.08) (19.12) (15.84) (9.56) (5.93)
Working Capital
— (6.50) (10.13) 23.17 7.72 (7.80) (1.97) 0.82
Capital Expenditures
— (0.43) (0.10) (0.25) (0.25) (0.07) — —
Net Current Asset Value
— (36.72) (54.33) 23.17 (1.47) (19.01) (20.32) (14.62)
EV/EBIT
— 0.00 — — — — — —
Capex to Sales
— 0.62 0.00 0.00 0.00 0.00 — —
Net Profit Margin
— (3,451.60%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Price to Operating Income
— 0.00 — — — — — —
Other line items
Depreciation/Fixed assets
— 0.09 0.12 0.13 0.11 0.21 0.29 0.46
Cash ROIC
— 165.88% 119.53% (21.44%) (103.64%) 113.81% 102.02% 728.16%
Accounts Receivable Turnover
— 1.77 0.00 0.00 — — — —
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — 0.00 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — 0.00 0.00 0.00 — — —
Average Receivables
— 0.39 0.39 0.14 — — — —
Average Payables
— 2.80 2.80 3.07 4.41 4.87 3.32 3.08
Average Assets
— 0.65 2.93 22.40 30.86 13.01 5.14 9.98
Average Common Equity
— (45.10) (45.10) (15.05) 11.69 (9.23) (18.82) (16.91)

Fold the line items

Columns are period end dates